Gabapentin Market Analysis

Global Gabapentin Market Overview

The Gabapentin Market Size was valued at USD 2.2 Billion in 2022 and is projected to grow from USD 2.3 Billion in 2023 to USD 3.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2032). Neuropathic pain and seizures are becoming more common, and the use of drugs for pain management is growing, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Gabapentin Market Trends

• Increasing usage as a pain management drug is driving the market growth

The growing use of gabapentin as a painkiller, especially for neuropathic pain, is one of the main factors driving the demand for the medicine. The increasing prevalence of chronic pain problems including diabetic neuropathy, shingles, and spinal cord injuries, which are challenging to treat with traditional opioids, is what is driving this market. The medicine was initially created and prescribed for epilepsy and seizures, but in recent years, the number of doctors who are prescribing gabapentin "off-label" for both acute and chronic pain has increased five-fold. While some prescribe it in addition to opioids, others even prescribe it in instead of them.

The sector is being driven by the rising demand for generic medicine formulations, which are less expensive than name-brand medications. Due to their accessibility and affordability, generic medications are growing in popularity, especially in developing nations with constrained healthcare budgets. Where there is a significant need for accessible healthcare, this trend is anticipated to fuel the market expansion of the gabapentin in the Asia Pacific region.

The market's growth is further fueled by awareness efforts like National Epilepsy Awareness Month in November, which work to raise knowledge and encourage action to comprehend and control the illness. Furthermore, medical professionals prefer to prescribe gabapentin over opioids in order to significantly reduce drug addiction. It is anticipated that this will increase the demand for the medicine.

The market of gabapentin is expanding because to gabapentin's expanding availability in a variety of dosage forms and formulations. It is offered as topical gels and creams, oral capsules, pills, and solutions. To increase the drug's efficacy and safety, manufacturers are also creating novel formulations and delivery systems. Thus, driving the Gabapentin market revenue.

Gabapentin Market Segment Insights

Gabapentin Dosage Form Insights

The Market segments of Gabapentin, based on Dosage Form includes tablet, capsule, and oral solution. The market for gabapentin was dominated by the capsule category in 2022. The quicker mechanism of action and greater acceptance of the dose form are credited with the segment's domination. Additionally, the market is expanding due to the high incidence of prescriptions for capsules and the accessibility of well-known brands in the industry, such Neurontin and Gralise. The most common dosages of these capsules are 100 mg, 300 mg, and 500 mg. Due to its high consumption rate and widespread availability of tablets, the tablet category is anticipated to exhibit a profitable CAGR during the projection period. Major products like Horizant and Neurontin are present, which boosts revenue generating.

Gabapentin Type Insights

The Gabapentin Market segmentation, based on Type, includes generic and branded. Due to low market entry barriers that encouraged more people to enter the market and increased consumer preference for generics, the generic segment had the greatest revenue share in 2022. Zydus Lifesciences got FDA approval in February 2023 for 300 mg and 600 mg gabapentin tablets, suggesting a market with a favorable regulatory environment for generics. However, the company's Indian facility is anticipated to produce the product. The sale of generic versions of the medication is the primary emphasis of major generic producers including Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma.

Gabapentin Application Insights

The Market segmentation of Gabapentin, based on Application, includes epilepsy, neuropathic pain, restless legs syndrome, and others. The biggest revenue share was held by the epilepsy segment in 2022, and it is projected that it would continue to dominate during the forecast period. The global rise in the prevalence of active epilepsy, which necessitates ongoing pharmaceutical assistance for seizure treatment, is blamed for the domination. The adoption of gabapentin is anticipated to be hampered in middle- and lower-income countries, where over 80% of the 50 million people who suffer from epilepsy reside and lack access to basic treatments. Due to the increased prevalence of the ailment and the rising acceptance of therapies, the neuropathic pain category is anticipated to experience the quickest CAGR throughout the projection period.

Figure 1: Gabapentin Market, by Application, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Gabapentin Distribution Channel Insights

Based on distribution channel, the Gabapentin Market segmentation has been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. The hospital pharmacy segment was expected to hold the largest market share in 2022. The segment has a competitive advantage due to the ease of access to pharmaceuticals and reimbursement options at these pharmacies. These pharmacies also have direct access to patient information, which improves the accuracy of the medicine administration. These pharmacies, which do not have the authority to dispense medication, work to lower total costs by encouraging the use of generics.

Gabapentin Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America held the biggest market revenue share of gabapentin in 2022, and it is anticipated that it will continue to hold this position during the forecast period. The high incidence of neurological diseases and ailments characterized by persistent discomfort in the area may be to blame for the dominance. Regional expansion, however, is anticipated to be curtailed by the market's increasing number of gabapentin overdose instances. The FDA is in favor of generic drug launches in the area, which will increase product availability in the United States. Further, the U.S. market of Gabapentin held the largest market share, and the Canada market of Gabapentin was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Gabapentin Market SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Gabapentin market accounts for the second-largest market share. The regional market is anticipated to be driven by the rising desire for anti-convulsants, government initiatives, and product approvals. Due to the growth in point-of-care diagnostics, technological improvements, and untapped prospects in emerging regions, Europe is also anticipated to have a sizeable market share. Further, the German market of Gabapentin held the largest market share, and the U.K. market of Gabapentin was the fastest growing market in the European region.

The Asia-Pacific Gabapentin market is expected to grow at the fastest CAGR from 2023 to 2032. Due to growing knowledge of gabapentin's advantages over opioids and rising healthcare spending in developing nations like India and China, the Asia-Pacific region is anticipated to have significant development throughout the forecast period. The expansion in Asian nations is further fueled by the presence of important generic players like Aurobindo Pharma, Sun Pharmaceutical Industries Limited, and Zydus Lifesciences. This region primarily consists of emerging countries with lesser incomes, which makes the market more appropriate for generic goods. Further, China’s market of Gabapentin held the largest market share, and the Indian Gabapentin market was the fastest growing market in the Asia-Pacific region.

Gabapentin Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their Product lines, which will help the market of Gabapentin, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Gabapentin Industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Gabapentin Industry to benefit clients and increase the market sector. In recent years, the Gabapentin Industry has offered some of the most significant advantages to medicine. Major players in the market of Gabapentin, including Zydus Pharmaceuticals, Inc, Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Amneal Pharmaceuticals LLC., Cipla USA, Inc., BP Pharmaceuticals Laboratories Company, Assertio Holdings, Inc., Arbor Pharmaceuticals, Inc., Pfizer Inc., are attempting to increase market demand by investing in research and development operations.

Biopharmaceuticals are discovered, developed, produced, and sold by Pfizer Inc. The business sells goods to cure a range of ailments, including cancer, inflammation, rare diseases, metabolic, cardiovascular, and metabolic and pain disorders, as well as women's health issues. Additionally, it offers contract manufacturing services, sterile injectable drugs, biosimilars, active pharmaceutical ingredients (APIs), and medicines. Pfizer offers its goods through distributors, merchants, pharmacies, hospitals, private physician offices, clinics, and public institutions. India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US are all home to significant manufacturing facilities for it.

Generic and speciality medications are discovered, developed, produced, and sold by Teva Pharmaceutical Industries Ltd (Teva). The business offers specialized medications to treat ailments including cancer, respiratory, dermatological, women's health, and central nervous system (CNS) disorders. In addition to capsules, pills, injectables, liquids, inhalants, creams, and ointments, it also offers generic medications in a variety of dosage forms. Along with active pharmaceutical ingredients (APIs), Teva also sells over-the-counter (OTC) goods. It concentrates on creating new generic medications. Through a network of subsidiaries in areas including North America, Europe, and International Markets, the corporation manages its global activities. Tel Aviv, Israel serves as the home base for Teva. Teva declared that a generic version of gabapentin would go on sale in the United States in 2021.

Key Companies in the market of Gabapentin include

• Zydus Pharmaceuticals, Inc


• Glenmark Pharmaceuticals Limited


• Sun Pharmaceutical Industries Ltd.


• Ascend Laboratories, LLC


• Apotex Inc.


• Teva Pharmaceutical Industries Ltd.


• Aurobindo Pharma.


• Amneal Pharmaceuticals LLC.


• Cipla USA, Inc.


• BP Pharmaceuticals Laboratories Company


• Assertio Holdings, Inc.


• Arbor Pharmaceuticals, Inc.


• Pfizer Inc.

Gabapentin Type Developments

April 2020 The introduction of a gabapentin generic in the United States was announced by Mylan.

January 2020 The introduction of a gabapentin generic in the United States was announced by Hikma.

Gabapentin Market Segmentation

Gabapentin Dosage Form Outlook

• Tablet


• Capsule


• Oral Solution

Gabapentin Type Outlook

• Generic


• Branded

Gabapentin Application Outlook

• Epilepsy


• Neuropathic Pain


• Restless Legs Syndrome


• Others

Gabapentin Application Outlook

• Hospital Pharmacy


• Retail Pharmacy


• Online Pharmacy

Gabapentin Regional Outlook

• 
  

  North America

  
  
  
  
  • US.
  
  
  • Canada
  
  
  
  


• 
  

  Europe

  
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  

  Asia-Pacific

  
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America